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NF-κB signaling, acting through NFKB1 dependent canonical and NFKB2 dependent
non-canonical pathways plays a critical role in inflammatory and immune responses.
Recent studies have associated mutations in these two genes with a common
variable immunodeficiency (CVID). While evaluating a female patient seeking a diagnosis
explaining her recurrent infections, we found a novel heterozygous c.1831C > T
(p.Arg611∗) nonsense mutation in the NFKB2 gene which introduces a Stop codon in
the ankyrin repeat domain of p100. Whole exome sequencing (WES) analysis, followed
by Sanger sequencing, identified this previously unknown mutation in two other family
members. Penetrance of the c.1831C > T variant was assessed by flow-cytometry and
protein expression in peripheral blood mononuclear cells (PBMC); whereas, activation
of the NF-κB2 signaling pathway was examined through immunoblotting and real-
time PCR. Heterozygous c.1831C > T variant led to the expansion of lymphocyte
B subpopulations with concomitant reduction of plasmablasts, low IgG levels, and
accumulation of p52 in PBMC. On the other hand, tested subjects had normal levels
of IgM, IgA, IgE and no impairment in lymphocytes proliferation. Although evaluated
patients did not fulfill all clinical features of CVID, their health should be monitored in
the future for possible late manifestation of the disease. In conclusion, we showed that
NFKB2 haplodeficiency caused by c.1831C > T nonsense mutation is asymptomatic,
possibly due to the compensatory mechanisms and allele redundancy.
Keywords: NF-κB signaling, NFKB2 gene, nonsense mutation, common variable immunodeficiency, whole exome
sequencing
INTRODUCTION
The human NFKB2 gene locus (chromosome 10q24) encodes a p100/p52 transcription factor
that belongs to the NF-κB signal transduction pathway. In mammals, this family consists of five
members: p65 (RelA), RelB, c-Rel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). The canonical
pathway, which includes NF-κB1, mediates a broad spectrum of inflammatory responses; whereas,
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B-cell survival and maturation, lymphoid organogenesis,
dendritic cell activation, and bone metabolism are regulated
by the non-canonical NF-κB2 pathway (Hayden and Ghosh,
2011; Sun, 2012). In the non-activated resting state, homo- and
heterodimer of NF-κB proteins are retained in the cytoplasm by
their association with inhibitory IκB proteins or by interaction
with the C-terminal Iκ-homologous domain within their
structure. Thus, full-length NF-κB1 (p105) and NF-κB2 (p100)
proteins act as their own inhibitors (Figure 1C). For these
proteins, proteasomal processing is required before translocation
to the nucleus, where NF-κB1 (p50) and NF-κB2 (p52) bind
to their target genes. Activation of NF-κB2 is triggered by
signaling from a subset of TNFR members leading to NF-κB
inducing kinase (NIK) accumulation in the cytoplasm. NIK
triggers a kinase leading to phosphorylation of p100 at two
conserved C-terminal serines (Ser866, Ser870) by IKKα kinase.
This is followed by ubiquitination of lysine 855 and subsequent
proteasomal processing, removing C-terminus from p100 to
generate p52. Heterodimer of p52 and RelB is then translocated
into the nucleus where this active complex acts as a transcription
factor (Oeckinghaus et al., 2011).
Common variable immunodeficiency (CVID) is one of
the most common primary immunodeficiencies, occurring
in approximately 1:10,000 to 1:50,000 people. CVID is a
clinically and genetically heterogeneous disorder characterized
by recurrent infections, antibodies deficiency, defects in B-cell
differentiation, and T cell abnormalities (Bonilla et al., 2016).
Genetic defects responsible for CVID have been identified in
less than 10–15% of all cases and include mutations in genes
involved in lymphoid organogenesis and B-cell survival and
maturation (Kienzler et al., 2017). Among them, there are
also genetically defined patients with CVID and mutations
in the NFKB1 and NFKB2 genes. To date, 9 mutations in
NFKB2 have been recognized in patients diagnosed with
CVID. Such patients were characterized by early-onset CVID
associated with autoimmunity, reduction in circulating B cells,
adrenocorticotropic hormone deficiency, and occasional other
pituitary hormone deficiencies. Interestingly, all of these reported
mutations alter the amino acid sequence near the C-terminus
of p100, a region crucial for NIK mediated p100 processing. As
a result, p100 phosphorylation is blocked, inhibiting processing
into the −52 active form and preventing nuclear translocation
(Chen et al., 2013; Brue et al., 2014; Lee et al., 2014; Lindsley
et al., 2014; Liu et al., 2014; Lougaris et al., 2015; Shi et al.,
2016). This pathophysiological mechanism is mimicked in
Nfkb2 Lym1 mutated mice containing a non-processable form
of p100 protein due to the p.Tyr868∗ nonsense mutation
(Tucker et al., 2016). In addition, Kuehn and coworkers recently
found two new heterozygous NFKB2 mutations (p.Glu418∗
and pArg635∗) resulting in constitutive p100/p52 activation,
nuclear localization and gene transcription (Kuehn et al., 2017).
Interestingly, mutations were found in both the asymptomatic
subjects and patients suffering from immunodeficiency
(Kuehn et al., 2017).
In our study, while evaluating a female patient suffering
from recurrent infections and her relatives, we found a novel
c.1831C > T (p.Arg611∗) nonsense mutation in the NFKB2 gene
FIGURE 1 | NFKB2 c.1831C > T nonsense mutation. (A) Pedigrees of tested
family, arrows indicate family members diagnosed with c.1831C > T
(p.Arg611∗) nonsense mutation that were seeking a genetic testing.
(B) Schematic representation of p100 domains showing rel homology domain
(RHD), ankyrin repeat domain (ARD), and death domain (DD). Black arrow
indicate processing position of p100, the location of the conserved lysine
(K855) and two conserved serine s (S866 and S870) is also depicted on the
scheme (Wietek and O’Neill, 2007, modified). Multiple sequence alignment of
amino acid sequences in the fragment of ARD domain. (C) Sanger
sequencing of two individuals over the c.1831 position. Left panel shows
wild-type c.1831 position (mother, I.3) and right panel shows the c.1831C > T
variant (daughter, II.1). (D) High resolution melt analysis of DNA product
amplified in the real-time PCR reaction. 49 bp amplicons generated over
mutated nucleotide were analyzed by HRM. Only one product is detected in
control subjects, whereas all three samples collected from NFKB2
haplodeficient subjects generated a bimodal melt curve, together with a shift
toward lower melting temperature.
that introduces a Stop codon in the ankyrin repeat domain (ARD)
of p100. This mutation resulted in the expansion of lymphocyte
B subpopulations with concomitant reduction of plasmablasts,
low levels of IgG, and accumulation of p52 in peripheral blood
mononuclear cells (PBMC).
RESULTS
Genetic Analysis and Exome Sequencing
We collected a venous blood sample from a 28-year old female
patient who was seeking a diagnosis explaining her recurrent
infections and general ill health of unknown cause. The family
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history was insignificant apart from a history of a poorly
described chronic childhood disease in her paternal uncle
which was treated with IV IgG. Together with the Proband
sample (II.1), we collected blood from three other family
members, namely: father (I.2), his monozygotic twin brother
(the paternal uncle, I.1) and mother (I.3) (Figure 1A). Genomic
DNA was isolated after each subject provided written informed
consent, in agreement with the Bioethics Committee at the
Jagiellonian University in Krakow. Whole exome sequencing
(WES) was performed to the mean depth of 45×, 77% of
target was covered min. 20×, 89% – min. 10×. After variant
filtration by exclusion of those reported as common (minor allele
frequency >0.01), we focused on homozygous or potentially
compound heterozygous variants (compatible with recessive
inheritance) and ultrarare monoallelic variants predicted to
cause a loss/decrease of function (Supplementary Table S1).
Our approach led to the prioritization of a novel nonsense
mutation in the coding exon (17th exon consisting of 169
nucleotides) of the NFKB2 gene, namely chr10:104160444,
C > T NM_001077494.3:p.Arg611∗/c.1831C > T. This
monoallelic mutation was identified in the DNA isolated
from individuals I.1; I.2, and II.1 but not I.3 (Figure 1A and
Supplementary Figure S1) and was confirmed by Sanger
sequencing (Figures 1B,C). The mutation was absent in the
GnomAD database1 as well as from our in house database of
>1000 Polish exomes. The c.1831C > T nonsense mutation,
as described by us, is localized in the ARD domain of the
p100 protein but it was unknown whether the mutated allele is
expressed and whether this leads to translation of the truncated
protein (Figure 1). To verify the presence of mutated mRNA
in patients’ cells, we analyzed mRNA isolated from blood
leukocytes. As shown in Figure 1D, a quantitative, high-
resolution melt (HRM) analysis of a DNA fragment – a PCR
product generated over a mutated nucleotide – indicated only
one product in control patients. On the other hand, all three
samples collected from NFKB2 haplodeficient subjects generated
a bimodal melt curve together with a shift toward lower melting
temperature (Figure 1D and Supplementary Figure S2A).
Additionally, Sanger sequencing of the same amplicon
revealed that mutated transcripts represented 24–30% of
all (Figure 2).
Clinical Findings
Data from mouse models show that disrupted NF-κB2 signaling
adversely affects both T and B cell function (Franzoso et al.,
1998; Caamaño et al., 1998). Additionally, recently described
mutations in humans leading to non-processable p100 were
associated with the development of a common variable
immunodeficiency (Chen et al., 2013; Lee et al., 2014; Lindsley
et al., 2014; Liu et al., 2014). CVID in these patients was
diagnosed at various ages and was linked to nonfunctional
p100 protein. In contrast, according to medical records, only
proband (II.1), and not two other subjects with c.1831C > T
nonsense mutation, suffered from recurrent infections. Analysis
of peripheral blood samples from proband’s father (I.2) and
1http://gnomad.broadinstitute.org
FIGURE 2 | Analysis of wild type and mutated NFKB2 transcripts. RNA
isolated from leukocytes was used for cDNA synthesis. Sanger sequencing
was performed on cDNA product generated after PCR over the c.1831
position. Wild-type and mutated transcripts were detected in all individuals
characterized by c.1831C > T mutation.
uncle (I.1) (subject II.1 was no longer available for blood analysis)
revealed no abnormalities in lymphocytes subpopulations –
total lymphocyte count, lymphocytes T and B, and NK cells
were all within normal range (Table 1). We detected only a
slightly decreased number of red blood cells in both individuals
4.34 and 4.24 mln/µL (normal range 4.30–5.80 mln/µL) in
I.1 and I.2, respectively (Supplementary Table S2). Also, both
men had normal numbers of circulating CD4+ and CD8+
T cells (Supplementary Table S3). Immunophenotyping of
naïve, central memory, effector memory, and TEMRA cells also
revealed no abnormalities (Supplementary Table S3).
Further analysis of lymphocyte B subpopulations was
performed according to EUROclass classification (Wehr
et al., 2008). The circulating B-cell pool consists of up to 6
distinct subpopulations (Table 2) and the distribution of these
subpopulations reflects differentiation of B cells in primary and
secondary lymphoid tissue. In both subjects, we detected normal
B-cell numbers (216 and 177 cells/µL, normal range 100–500,
11.4 and 8.2% of lymphocytes, normal range 6.0–19.0%), and
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TABLE 1 | Leukocyte classes in subjects with mutation in NFKB2 gene.
Subject I.1 I.2 Normal range
Lymphocyte subpopulations
Total lymphocyte count (cells/µL) 1892 2160 1000–3400
lymphocytes (% of WBC) 35.7% 40% 16.0–44.0%
CD3+ (cells/µL) 1470 1348 700–2100
CD4+ (cells/µL) 713 795 300–1400
CD8+ (cells/µL) 630 497 200–900
CD19+ (B cells, cells/µL) 216 177 100–500
CD3-CD16+CD56+ (NK cells, cells/µL) 210 626 90–600
CD3-CD16+CD56+ (NK cells, % of
lymphocytes)
11.1% 29% 7–31%
Normal values were taken from the EUROclass trial published by Wehr et al. (2008).
Abnormal values are highlighted in bold.
TABLE 2 | Laboratory findings in subjects with mutation in NFKB2 gene.
Lymphocyte B subpopulations I.1 I.2 Normal range
B cells: CD19+ (cells/µL) 216 177 100–500
B cells (% of lymphocytes) 11.4 8.2 6.0–19.0%
Memory B cells: CD19+CD27+ (% of
lymphocytes)
7.11% 5.26% 0.56–1.76%∗
Marginal zone B cells:
CD19+CD27+IgD+ (% of CD19+)
50.77% 52.7% 7.20–30.80%
Class-switched memory B cells:
CD19+CD27+IgD-IgM- (% of CD19+)
10.47% 9.69% 6.50–29.20%
Activated B cells:
CD21lowCD38lowCD19high (% of
CD19+)
13.09% 16.86% 1.60–10.00%
Total transitional B cells:
CD38++IgMhigh (% of CD19+)
10.85% 7.35% 0.60–3.50%
Plasmablasts:
CD38++IgM-CD21lowCD19low (% of
CD19+)
0.2% 0.18% 0.40–3.60%
Immunoglobulins
IgG (g/L) 6.19 6.46 7.00–16.00
IgA (g/L) 1.50 1.73 0.67–3.67
IgM (g/L) 0.68 1.06 0.41–2.30
IgE (IU/mL) <4.63 14.80 0.00–100.00
Complement
C3c (g/L) 0.90 0.98 0.75–1.36
C4 (g/L) 0.14 0.16 0.13–0.40
Lymphocyte proliferation assay
Phytohemagglutinin (stimulation index) 69 87 >10
Anti-T3 antigen antibodies (stimulation
index)
79 89 >10
Pokeweed mitogen (stimulation index) 74 105 >10
An asterix indicates normal values taken from the Freiburg classification (Warnatz
et al., 2002), with other normal values taken from the EUROclass trial published by
Wehr et al. (2008). Abnormal values are highlighted in bold.
normal percentage of class-switched memory B cells (10.47
and 9.69% of B cells, normal range 6.5–29.20%). However,
four B-cell subpopulations were expanded: memory B cells
(7.11 and 5.26% of lymphocytes, normal range 0.56–1.76%),
marginal zone B cells (50.77 and 52.7% of B cells, normal range
7.2–30.80%), activated B cells (13.09 and 16.86% of B cells,
normal range 1.10–6.90%), and transitional B cells (10.85 and
7.35% of B cells, normal range 0.60–3.50%) (Table 2). Of note
is that expansion of selected B-cell subclasses was not observed
among plasmablasts. In fact, we detected low numbers of these
cells (0.2 and 0.18% of B cells, normal range 0.40–3.60%) as
well as hypogammaglobulinemia (6.19 and 6.46 g/L, normal
range 7–16 g/L). Although immunoglobulin levels are usually
reduced in patients with CVID, we detected normal amounts of
IgA, IgM, IgE, and complement proteins (C3c, C4) (Table 2).
In the last set of experiments, we measured lymphocyte
proliferation in response to phytohemagglutinin (PHA),
pokeweed mitogen (PWM), and anti-T3 antigen antibodies,
knowing that this in vitro test provides a semiquantitative
assessment of total cell-mediated immunity. As shown in
Table 2, stimulation of cells with either PHA, PWM or anti-
T3 antibodies did not show any diminished proliferative
responses (Table 2).
Cytokines and chemokines play an important role in the
orchestration of leukocyte biology and changes in their profiles
were shown among CVID patients (Rezaei et al., 2008; Hel et al.,
2014; Varzaneh et al., 2014). In our study, out of 30 analytes, the
concentration of six (IL-2, IL-8, IL-15, IL-17, G-CSF, and IFN-A)
was below the limit of detection and remaining concentrations
were unchanged between subjects with the mutation and healthy
controls (Figure 3).
Expression of Mutant NF-κB2 Protein
NFKB2 is a highly conserved gene and human p100/p52 shares
92% identity at the amino acid level with mouse protein. Since
the c.1831C > T nonsense mutation identified by us might lead
to generation of a truncated protein (610 amino acids instead
of 900) deprived of regulatory residues Ser866, Ser 870, and
Lys855, we hypothesized that the expression pattern of p100/p52
protein might be altered in individuals with the mutation. We
assessed the level of p100/p52 proteins in peripheral blood
mononuclear cells isolated both from family members with the
mutation (I.1 and I.2) and unrelated control subjects (C1, C2,
C3). Presence of the mutation was associated with decreased
expression of the p100 subunit in PBMC but higher levels of
p52 subunit as compared to age-matched controls (Figure 4A),
which suggests an enhanced activation of the NFKB2 gene in
PBMC. Stimulation of PBMC for 3 h with Phorbol 12-myristate
13-acetate (PMA, 50 ng/mL) and ionomycin (1 µg/mL) did
not change the expression pattern in mutation carriers; we
detected low amounts of p100 and an accumulation of p52 in
comparison to the control PBMC (Figure 4B and Supplementary
Figures S3A,B). Interestingly, we did not detect any band
corresponding to the truncated form of protein consisting of
610 amino acids either in freshly isolated PBMC (Figure 4A)
or in cells stimulated in vitro (Figure 4B). Next, to exclude a
lineage-specific effect of the p.Arg611∗ mutation, we assessed
the level of p100/p52 proteins in the HepG2 cell line (human
hepatocellular carcinoma originated from endoderm) transiently
overexpressing the NFKB2 gene. We found very low levels of
p100 and p52 in cells transfected with empty plasmid (pcDNA)
or in the non-treated control (Figure 4C). Transfection with
plasmid harboring CDS of the NFKB2 gene (pcDNA-NFKB2) led
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FIGURE 3 | Plasma analysis. Plasma concentration of cytokines, chemokines and growth factors were measured by Human Cytokine Magnetic 30-Plex Panel. Filled
symbols indicate family members (I.1, I.2, II.1) diagnosed with c.1831C > T (p.Arg611∗) nonsense mutation. Concentrations of analytes in individuals were
compared to age- and sex-matched controls (Ctl F, Ctl M).
to overexpression of both p100 and p52 proteins. In contrast,
HepG2 cells transfected with plasmid encoding NFKB2 CDS with
point mutation (p.Arg611∗, pcDNA-NFKB2MUT) overexpressed
p52 but not p100. Additionally, in these cells, we detected a band
(at ∼80 kDa) corresponding to a truncated form of p100/p52
protein (Figure 4C). Higher expression of p52 in cells transfected
with pcDNA-NFKB2MUT in comparison to pcDNA-NFKB2 is
in accordance with data obtained from PBMC. However, lack
of truncated protein in vivo implies very low expression levels
and/or a more complex mechanism of transcription and/or
translation regulation.
To test for levels of non-canonical p100/p52 activation,
we used real-time PCR to assay CXCL13, CCL19, and
MADCAM1, known targets of the NFKB2 pathway. Firstly, we
detected a reduced amount of NFKB2 transcript in patients
with p.Arg611∗ mutation and tested whether it influences
expression of genes regulated by p100/p52 transcription factor
(Figures 5A–D and Supplementary Figure S2B). However, there
was no clear pattern of CXCXL13 expression in subjects with
mutation in comparison to controls: expression is higher (I.1),
equal to (I.2) or lower than (II.1) in controls (Figure 5B).
Similar results were obtained for two other genes; CCL19
and MADCAM1, also regulated by p100/p52 transcription
factor (Figures 5C,D).
DISCUSSION
In this study, we demonstrate that heterozygous c.1831C > T
(p.Arg611∗) nonsense mutation in the NFKB2 gene does
not have an obvious clinical manifestation. Both analyzed
patients do not suffer from severe infections, do not require
repetitive immunoglobulin substitution therapy, and have no
autoimmune manifestation. Laboratory analysis revealed that
they fulfill only some criteria for CVID diagnosis. In 2008,
after examination of 303 European CVID patients, a novel
classification (EUROclass) of CVID subgroups based on detailed
analysis of B lymphocytes was proposed (Wehr et al., 2008).
Initially, EUROclass distinguishes between CVID patients with
less or equal to 1% B cells (group B-) and those with more
than 1% B cells (group B+). Group B+ patients included
90% with hypogammaglobulinemia that were enrolled in the
study. Patients characterized by us, similarly to 29 subjects from
the EUROclass trial, were classified as group B+smB+21low,
based on the following criteria: more than 1% of B cells
(B+), more than 2% of switched memory B cells (smB+),
and expansion of CD21low activated B cells. Importantly, the
classification of CVID based on B-cell immunophenotyping
cannot be the sole technique used for diagnosis. As emphasized in
“International Consensus Document (ICON): Common Variable
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FIGURE 4 | Expression of p100/p52 protein. (A) Immunoblot of whole-cell
lysates from PBMC isolated from individuals with c.1831C > T mutation (I.1,
I.2) and wild-type controls (C1, C2, C3). (B) Immunoblot of whole-cell lysates
from freshly isolated PBMC and cells stimulated for 3 h with phorbol
12-myristate 13-acetate (PMA, 50 ng/mL) and ionomycin (1 µg/mL). Cells
were isolated from family members (I.1, I.2) and wild-type controls (C1, C2,
C3). (C) Before immunoblot analysis, HepG2 cells were transfected with
expression vectors encoding coding sequence of wild-type NFKB2 gene
(pcDNA-NFKB2), or c.1831C > T mutated variant (pcDNA-NFKB2MUT).
Immunodeficiency Disorders” published by a committee of
immunology experts, patients should be diagnosed according to
revised CVID criteria, taking into consideration the following
aspects: (i) hypogammaglobulinemia must be accompanied by
low levels of IgA or IgM; (ii) CVID patients should have
an impaired response to either T-dependent or T-independent
stimuli; (iii) differential diagnosis of hypogammaglobulinemia
to exclude other diseases should be performed (Bonilla et al.,
2016). Of note, most CVID patients will have at least 1 of the
characteristic clinical manifestations (infection, autoimmunity,
lymphoproliferation), however, the disease might also be
diagnosed in asymptomatic individuals (Bonilla et al., 2016).
Importantly, slightly different CVID criteria were proposed by
other authors. For example, Ameratunga et al. (2014) suggested
a cutoff <5 g/L for IgG concentration in all CVID patients,
in contrast to the ICON document, wherein the authors
recommend analysis based on regional clinical laboratory norms.
Study of consanguineous families with several members
of CVID-like phenotype helped to identify genetic defects
responsible for CVID development. Firstly, described mutated
genes such as CD19, CD20, CD21, CD81, or ICOS affected B
cell activation (Grimbacher et al., 2003; van Zelm et al., 2006,
2010; Warnatz et al., 2009; Kuijpers et al., 2010; Thiel et al.,
2012). The list of mutations leading to CVID development is
growing but genetic defects responsible for CVID still account
for less than 10–15% of all cases (Salzer et al., 2012). Recent
genome-wide association and whole genome sequencing studies
have shown that whereas polygenic inheritance is frequent, a
distinct monogenic cause of disease, including a defect in NFKB2,
can be identified in a subset of CVID patients (Shi et al.,
2016; Kienzler et al., 2017). To date, nine different mutations
in the NFKB2 gene, including point mutations, insertion, and
deletions resulting in CVID development have been described.
In all individuals characterized so far, NF-κB2/p100 processing
and nuclear translocation were abrogated reflecting clinical
manifestation of the disease (Chen et al., 2013; Brue et al.,
2014; Lee et al., 2014; Lindsley et al., 2014; Liu et al., 2014;
Lougaris et al., 2015; Shi et al., 2016). Whereas we cannot
exclude that lack of penetrance in our family is caused by
unidentified genomic variants, it is important to emphasize the
NFKB2 mutations described so far also change the amino acid
sequence near the C-terminus of p100 and are associated with
variable penetrance (Kuehn et al., 2017). The C terminus is
crucial for NIK mediated p100 processing and lack of regulatory
K855, S866 or S700 prevents the processing of the inhibitory
precursor p100 into the active subunit p52. As a result, as
described by Chen and coworkers, the level of p52 was reduced
and p52 translocation to the nucleus was inhibited (Chen et al.,
2013). In contrast to previously characterized mutations, Kuehn
and coworkers identified two heterozygous nonsense mutations,
p.Glu418∗ and pArg635∗, leading to constitutively active forms
of p100/p52 associated with an immunodeficiency phenotype
(Kuehn et al., 2017). One would expect, that changed amounts,
or ratios of p100/p52 proteins would lead to altered gene
expression. Indeed, besides well know non-canonical pathway,
p100 was shown to sequester and inhibit NF-κB through
formation of so called kappaBsomes (Tao et al., 2014). The unique
ability of p100 to interact with all NF-κB subunits by forming
kappaBsomes demonstrated its importance in regulation of
cellular homeostasis by coordinating gene expression programs
(Tao et al., 2014).
Clinical manifestation of p.Glu418∗ and pArg635∗ gain-
of-function mutations included hypogammaglobulinemia, and
recurrent upper and lower respiratory tract bacterial infections,
all frequently described in CVID patients. However, the
patients also developed problems not characteristic for CVID.
Interestingly, both mutations were also detected in two
asymptomatic carriers, thereby proving that immunological and
clinical penetrance may not be complete (Kuehn et al., 2017).
In line with this data, the p.Arg611∗ mutation identified by
us causes no obvious clinical manifestation. However, both
patients analyzed in detail were characterized by expansion of
lymphocyte B subpopulations with concomitant reduction of
plasmablasts and hypogammaglobulinemia, all characteristic for
CVID. Although T cell abnormalities together with alternations
in cytokine production have also been described in CVID
patients, we did not detect any changes in these parameters
(Varzaneh et al., 2014; Azizi et al., 2016, 2017). We also compared
obtained results with recently published paper by Kachamakova-
Trojanowska et al. (2018) who analyzed a cohort of 35 control
samples by the same method. We found no difference in
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FIGURE 5 | Real-time PCR analysis. (A) Expression of NFKB2 gene in 10 controls (C) and analyzed subjects (I.1, I.2, II.2). Analysis of genes regulated by p100/p52
transcription factor: (B) CXCL13, (C) CCL19, and (D) MADCAM1. ∗p < 0.05.
plasma concentrations of measured analytes between subjects
with c.1831C > T mutation and control ones.
A lower amount of NFKB2 transcripts in subjects with
p.Arg611∗ prompts speculation that the nonsense mutation
triggers elimination of mutant mRNA molecules by nonsense-
mediated decay (NMD) resulting in a decreased pool of p100
transcript. As a consequence, p52 protein might be stabilized
and accumulate in the PBMC. NMD is a surveillance pathway
that reduces errors in gene expression by eliminating mRNA
transcripts that contain premature Stop codons (Popp and
Maquat, 2013). The best-understood mechanism of NMD action
relies on pre-mRNA splicing and the presence of an exon
junction protein complex (EJC) on the mature mRNA molecules.
If during translation, the ribosome finds a Stop codon more
than 50 nucleotides “upstream” of EJC, the cell recognizes
mRNA as aberrant and destroys it (Popp and Maquat, 2013).
In our subjects, c.1831C > T mutation introduces a Stop codon
in the 17th exon, 137 nucleotides “upstream” of the exon
junction complex and, according to current knowledge, should be
assigned for NMD mediated degradation. In fact, sequencing of
DNA product confirmed that mutated transcripts represent only
between 24 and 30% of all NFKB2 mRNAs. Such results might
suggest either a lower transcription rate of mutated allele or a
shorter half-life of mutated mRNA.
Lastly, expansion of four B-cell subpopulations in the analyzed
subjects prompted us to check whether a nonsense mutation
at a similar location in NFKB2 was reported in lymphomas.
Interestingly, in CVID patients, there is an enhanced incidence
of several cancers, including lymphoma (Mortaz et al., 2016).
However, there is no data on whether a specific genetic
background might be the most prevalent cause of lymphoma in
this group of patients. In fact, rearrangements of the NFKB2 gene
have been associated with both B-cell and T-cell malignancies.
Such lymphomas are characterized by truncated p100 proteins
that lack some of the C-terminal ankyrin repeats. A p100 mutant
variant called p100HB originates from a nonsense mutation in
the 21st exon of NFKB2, resulting in a protein lacking the last
125 amino acids. Protein p100HB was identified in several well-
known human tumor cell lines derived both from B-cells (Daudi
cell line) or T-cells (Jurkat cell line) (Derudder et al., 2003).
HuT78 is another cell line originated from Cutaneous T cell
lymphoma with mutated NFKB2. Kim and coworkers identified
a protein consisting only of 666 amino acids (called p80HT) with
the addition of a short (serine-alanine-serine) fusion at the 3′
end of p80HT. Interestingly, direct truncation at aa666 was fully
inhibitory, as was a substitution of three alanines for the SAS
residues. What is more, the presence of as few as two C-terminal
ankyrin motifs in a protein consisting of 552 amino acids only
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was sufficient for inhibition of NF-κB-mediated transcriptional
activation (Kim et al., 2000). Besides NFKB2 nonsense mutations
detected in lymphomas, there is also a report of p.Arg609∗
mutation that was found in thyroid carcinoma. This mutation
has been described in the COSMIC database and generates a
protein shorter of just 2 amino acids than p.Arg611∗ (Catalogue
of Somatic Mutations in Cancer, 2018). Although the actual
C-terminal sequence of each of these proteins is distinct, the
common C-terminal deletions suggest that this alteration may be
important in changing the function of the NF-κB2 proteins.
In summary, we found a novel c.1831C > T (p.Arg611∗)
nonsense mutation in the NFKB2 gene, that introduces a Stop
codon in ankyrin repeat domain (ARD) of p100. Various
nonsense mutations in NFKB2 gene were described to cause
CVID, but patients evaluated by us were asymptomatic. They
were characterized by expansion of lymphocyte B subpopulations
with concomitant reduction of plasmablasts, low level of IgG
and accumulation of p52 in peripheral blood mononuclear cells
(PBMC) but did not fulfill other clinical features of CVID. Finally,
in our opinion, the health status of c.1831C > T (p.Arg611∗)
mutation carriers should be monitored in the future for possible
late manifestation of the disease.
MATERIALS AND METHODS
Subjects
Venous blood samples were collected from four family members:
a 28-year old female patient (II.1), her uncle (I.1), father (I.2),
mother (I.3) and unrelated control subjects. Informed consent
for participation in the study and for the publication of this
case report was obtained from all individuals and the study
was approved by the Bioethics Committee at the Jagiellonian
University in Krakow.
Clinical Laboratory Studies
The levels of serum complement components C3 and C4 and
total serum IgG, IgM and IgA and IgE concentrations were
determined by nephelometry (Dade Behring/Siemens, Deerfield,
IL, United States) using commercially available kits.
In vitro Lymphocyte Proliferation Assay
Peripheral blood mononuclear cells were isolated from EDTA-
treated peripheral blood by standard Ficoll density gradient.
Isolated cells were resuspended in culture medium (RPMI-1640)
supplemented with 10% fetal calf serum and antibiotics. Cells
were cultured in microtiter plates (1 × 105 per well) at 37◦ with
5% CO2 for 72 h with following stimulants: phytohemagglutinin
(PHA; 8 µg/mL), pokeweed mitogen (PWM; 2 µg/mL), or OKT3
(antibody to the T3 antigen of human T cells; 1 µg/mL). For
the last 17 h of culture, the cells were pulsed with 1 µCi/well
[3H]thymidine. Radioactivity of [3H]thymidine incorporated
into cellular DNA was measured in a β scintillation counter
and expressed as counts per minute (cpm). Stimulation index of
lymphocyte proliferation was calculated as ratio of cpm signal
after stimulation in comparison to unstimulated cells. Normal
response to stimulants was considered at stimulation index
greater than ten.
Analysis of Peripheral Cell Subsets by
Flow Cytometry
Enumeration of lymphocyte subsets was performed on EDTA-
treated peripheral blood patients’ samples. In case of T cell
subsets, peripheral blood cells were incubated with antibodies
directly. In evaluating of B cell subsets, in purpose to detect
surface immunoglobulis, blood samples were thoroughly washed
in PBS prior to staining (to remove plasma immunoglobulins).
The cells were stained for 15 min at room temperature with
the following combinations of directly labeled monoclonal
antibodies: (1) CD3-FITC/CD16+CD56-PE/CD45-PerCP/CD4-
PE-Cy7CD19-APC/CD8-APC-H7 using BD Multitest 6-color
TBNK reagent (total lymphocyte enumeration); (2) IgD-FITC/
CD21-PE/CD45-PerCP/CD27-PE-Cy7/CD19-APC/CD38-Alexa
Fluor700/IgM-BV605 (B cell subsets enumeration); (3) CD3-
FITC/CD25-PE/CD28Per-CP-Cy5.5/CD45RA-PE-Cy7/CD4-Ale
xaFluor700/CD8-APC-H7/CCR7-BV421/CD27-BC501/CD127-
BV605 (T cell subsets enumeration). After incubation,
erythrocytes were lysed using BD FACS Lysing Solution
and washed twice in PBS (300 × g, 10 min, 4◦C). Then, after
two washing steps, the cells were resuspended in PBS and
analyzed using a BD FACSCantoTM 10-color flow cytometer
(BD Biosciences) using BD FACSDiva v.8.01 software. The list
mode data of 50,000 events in a “live gate” mode were acquired.
The cells were gated on lymphocytes according to forward
(FSC), side scatter (SSC) parameters and CD45 expression.
In case of B cell subsets, results were given as the percentage
of B cells and absolute counts per ml (due to EUROclass
classifications recommendations). In case of T cell subsets results
were presented as the percentage of lymphocytes and absolute
numbers. Reference ranges of B cell subsets were adopted from
EUROclass classifications.
Whole Exome Sequencing (WES)
Whole exome sequencing was performed using HiSeq 1500
platform. Libraries were made using Nextera DNA Library
Preparation Kit (Illumina). Bioinformatics analysis was
performed as described previously (Ploski et al., 2014). NFKB2
Sanger sequencing was performed to confirm genetic variants
detected by WES.
Specific pair of primers: For 5′-ATGCCTGACTTTGAGGG
AC-3′ and Rev 5′-ATGTCAGCACCAGCCTTCA-3′ was used
to amplify a 299 bp fragment of NFKB2 DNA. The amplified
cDNA was processed using Nextera XT Library Preparation Kit
(Illumina) and sequenced on HiSeq 1500.
Immunoblotting
Cell lysates of PBMC and HepG cells were prepared in
RIPA buffer with a Protease Inhibitor Cocktail (Roche) and
a Phosphatase Inhibitor Cocktail (Sigma-Aldrich). Lysates
were denaturated and subjected to SDS–PAGE electrophoresis.
Blots were performed with the following antibodies: p100/p52
(Cell Signaling), β-actin (Sigma-Aldrich) and horseradish
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peroxidase-conjugated secondary antibodies (Sigma-Aldrich).
Immunoblotting of β-actin was used as a loading control.
Gene Expression
Total RNA was isolated from patients’ and controls’ leukocytes
(after lysis of red blood cells) with a modified guanidinium
isothiocyanate method. Next 1 µg of RNA was reverse
transcribed into cDNA by M-MLV Reverse Transcriptase
according to vendor’s protocol (Promega). Gene expression
was measured by real-time PCR (Illumina) with the following
specific primers: NFKB2 For 5′-ATGCCTGACTTTGAGGGAC-
3′ and Rev 5′-ATGTCAGCACCAGCCTTCA-3′; CXCL13 For
5′-GGACCCTCAAGCTGAATGGA-3′ and Rev 5′-AGCTTGAG
TTTGCCCCATCA-3′; CCL19 For 5′-GGTGCCTGCTGTA
GTGTTCA-3′ and Rev 5′-GCAGTCTCTGGATGATGCGT-3′;
MADCAM1 For 5′-GTGCTGTTCAGGGTGACAGA-3′ and Rev
5′-GTGCAGGACGGGGATGG-3′; EF2 For 5′-GACATCA
CCAAGGGTGTGCAG-3′ and Rev 5′-TCAGCACACTGGCA
TAGAGGC-3′. The relative quantification of genes’ expression
was calculated with the 2−1Ct method.
For sequence analysis on NFKB2 mRNA expressed in
leukocytes we used cDNA synthetized as described above. Next,
299 bp DNA product was generated by PCR (with Phusion
DNA polymerase with proof reading properties, Thermo Fisher)
with the following primers: NFKB2 For 5′-ATGCCTGAC
TTTGAGGGAC-3′ and Rev 5′-ATGTCAGCACCAGCC
TTCA-3′. Finally, Sanger sequencing was performed to verify if
mutated allele is expressed.
High Resolution Melt Analysis
One microgram of total RNA isolated from leukocytes was
reverse transcribed into cDNA by M-MLV Reverse Transcriptase
according to vendor’s protocol (Promega). Next, a real-
time PCR followed by high resolution melt (HRM) analysis
was performed with the following primers: HRM_F: 5′-
GTATCCAGTACACCTGGCGG-3′ and HRM_R: 5′-ATCCAGG
CACTCAGGGCTTC-3′. After 40 cycles of standard real-time
PCR reaction, 49 bp amplicons were analyzed by HRM according
to the protocol: incubation at 60◦C for 1 min followed by
temperature change from 60 to 95◦C with temperature ramp
0.1◦C/s combined with signal detection.
Cell Culture
HepG2 cells were cultured in DMEM LG with 10% fetal bovine
serum and 2 mM L-glutamine at 37◦C in a humidified 5%
CO2 incubator. Cells were routinely tested for mycoplasma
contamination by PCR.
Plasmids Construction
The expressing vector coding for NFKB2 (pcDNA-NFKB2) was
obtained by cloning of the PCR product to the mammalian
expressing vector pcDNA3. Briefly, human coding sequence
(CDS) of NFKB2 gene was amplified on cDNA template obtained
from PBMC isolated from healthy donor. Amplification was
done using the following specific primers For 5′-CCAAGC
TTTAGCCCAGAGACATGGAGAGT-3′ containing a HindIII
restriction site at 5′ end and Rev 5′-ATGAATTCTTGAAATA
GGTGGGGACGCTGTA-3′ containing an EcoRI restriction site
at 5′end. After digestion of the PCR product with HindIII/EcoRI
restriction enzymes the insert was cloned into pcDNA3 digested
with the same enzymes as the insert. Generation of vector
encoding a c.1831C > T nonsense mutation (p.Arg611∗, pcDNA-
NFKB2MUT) was done by PCR site-directed mutagenesis with
Phusion DNA Polymerase (Thermo Fisher Scientific) and the
following primers: For 5′-TCCGAGCCTGAAGCCCTGAGT-3′
and Rev 5′-CCGCCAGGTGTACTGGATACA-3′. All generated
vectors were sequenced, and their expression was confirmed by
western blot with a p100/p52 specific antibodies.
Luminex Analysis
Plasma concentrations of cytokines, chemokines and growth
factors were analyzed by Luminex R© Technology (Human
Cytokine Magnetic 30-Plex Panel, Life Technologies) in 96-well
plates according to vendor’s protocol. Briefly, samples were mixed
with buffer containing standards or specific antibodies bound
to microspheres and incubated for 2 h at room temperature.
Next, after buffer aspiration and washing with PBS, secondary
antibodies conjugated with biotin were added. Directly before
fluorescence measurement streptavidin-phycoerythrin complex
was added to all samples.
Statistical Analysis
Results are expressed as mean+SEM and were analyzed by
GraphPad Prism Software (GraphPad). Two tailed Student’s t-test
was used for comparison of two groups. The p-values are marked
with the asterisks in the charts (∗p < 0.05) and differences were
considered significant when p < 0.05.
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FIGURE S1 | NFKB2 sequencing. (A) Nonsense mutation c.1831C > T
(p.Arg611∗) was found after whole exome sequencing analysis in proband’s DNA.
(B,C) Presence of mutation was confirmed by Sanger sequencing in proband’s
sample and tested in other family members.
FIGURE S2 | Expression of mutated NFKB2 allele. (A) Raw data of high resolution
melt analysis. Real-time PCR was performed in triplicates and each curve
corresponds to one sample (one well in the 96-well real-time PCR plate). Black
curves represents control subjects, red curves represents subjects with
c.1831C > T mutation. (B) Real-time PCR analysis of NFKB2 expression in
leukocytes collected from 10 control patients and 3 carriers of nonsense mutation
c.1831C > T (p.Arg611∗).
FIGURE S3 | Densitometry analysis. Amount of p100 (A) and p52 (B) proteins
were evaluated by western blot and next quantified by densitometric
analysis.
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